Manipal Health IPO Review: Is India's Largest Private Hospital Network Built for the Long Term?

Manipal Health Enterprises, India's largest private hospital network by bed capacity, is coming to the stock market with a ₹9,275.22 crore IPO. The company operates 49 hospitals with over 13,000 licensed beds across the country, and most of the IPO proceeds will be used to reduce debt rather than fund expansion.

At first glance, the Manipal Health IPO looks expensive on the P/E ratio. But hospitals are capital-intensive businesses where accounting profits often understate operating performance because of high depreciation and interest costs. Does that make the valuation more reasonable than it appears? And can Manipal continue delivering strong growth while managing the debt from recent acquisitions?

In this review, we'll examine the business, growth opportunity, strengths, risks, valuation, and the key factors investors should consider before making a decision.

Manipal Health IPO Snapshot

Manipal Health IPO GMP

The Grey Market Premium (GMP) is an unofficial indicator of market demand and can change quickly based on investor sentiment. It does not guarantee listing gains or reflect an IPO's intrinsic value. Investment decisions should be based on the company's fundamentals, valuation, financial performance, and risk factors rather than relying solely on GMP. Read our detailed guide on IPO GMP to understand how it works, its limitations, and the factors that influence it.

What Does Manipal Health Actually Do?

Think of Manipal Health as a nationwide network of large multi-specialty hospitals rather than a single hospital. Just as a bank operates branches across different cities, Manipal operates hospitals across 14 states, allowing patients to access specialized treatment closer to home.

The company earns money from consultations, surgeries, diagnostic tests, medicines, emergency care, intensive care, and preventive health checkups.

Its patient mix is also well diversified. Nearly half of its inpatient revenue comes through health insurance companies, around one-third comes directly from patients paying out of pocket, while government healthcare schemes such as PM-JAY contribute another meaningful share. This reduces dependence on any single source of revenue and reflects the growing role of health insurance in India's healthcare system.

What also differentiates Manipal is its focus on complex treatments such as cardiac care, oncology, neurosciences, orthopedics, and kidney care. These procedures typically generate higher revenue than routine treatments. Supported by more than 11,000 doctors, advanced technologies such as robotic surgery, and one of the shortest patient stays among major hospital chains, the company is able to treat more patients using the same infrastructure. Going forward, management plans to expand both by building new hospitals and by acquiring existing hospital networks, a strategy it has already executed successfully several times.

Industry & Growth Opportunity

India's hospital industry is benefiting from several long-term structural trends rather than short-term demand. The healthcare delivery market is already worth around ₹7 lakh crore and is expected to grow to nearly ₹12.2 lakh crore by FY30, implying annual growth of around 10-12%.

The biggest reason is demographics. India's elderly population is steadily increasing, and older people generally require more frequent medical care for conditions such as heart disease, cancer, diabetes, and kidney disorders. At the same time, rising incomes are encouraging families to choose better-quality private hospitals instead of delaying treatment.

Another important tailwind is the expansion of health insurance. Insurance coverage has increased significantly over the past few years, making expensive treatments affordable for more people. Government schemes like PM-JAY are also bringing organized healthcare within reach of a larger section of the population, increasing patient volumes for established hospital chains.

Manipal appears well positioned to benefit from these trends because it already has a large presence across multiple cities and enjoys leadership positions in Bengaluru, Kolkata, and Pune. These hospitals often act as referral centers, attracting patients from surrounding towns for advanced treatments. Its efficient operations, reflected in the industry's shortest average patient stay of 2.78 days, also allow it to serve more patients without proportionately increasing capacity.

That said, industry growth alone does not guarantee success. Hospitals require continuous investment in buildings, medical equipment, and specialist doctors. Competition from established chains like Apollo, Max Healthcare, and Fortis remains intense, meaning operational execution will continue to matter as much as industry growth.

What Makes Manipal Health Strong?

Manipal combines scale with execution, and that combination is difficult to replicate. As India's largest private hospital network by bed capacity, it enjoys purchasing power that smaller hospital groups simply cannot match. Buying medicines and medical consumables in bulk helps control costs, while its presence across multiple cities creates a strong referral network for high-value treatments. This operating scale is one reason it has delivered the fastest revenue growth among major listed hospital chains over the past two years.

Operational efficiency is another standout strength. Patients spend an average of just 2.78 days in its hospitals, the shortest among major peers. A shorter hospital stay does not simply improve patient convenience. It also allows the company to free up beds faster and admit more patients using the same infrastructure. In a capital-intensive business where adding new hospital beds requires significant investment, better utilization directly supports revenue growth and profitability.

The company has also demonstrated an ability to grow through acquisitions rather than relying only on building hospitals from scratch. Previous acquisitions, including Columbia Asia, were integrated successfully while improving operating margins. Its negative working capital cycle further strengthens the business because it typically receives cash from patients and insurers before paying suppliers, supporting healthy cash generation and reducing dependence on short-term borrowings for daily operations.

What Are The Real Risks?

The biggest risk is concentration. Nearly half of Manipal's revenue comes from Karnataka alone. While the company operates across India, this dependence means that any regulatory changes, pricing restrictions, or operational disruptions in one state could meaningfully affect overall earnings.

Debt is another area investors should monitor closely. Recent acquisitions significantly increased borrowings, leading to a sharp rise in interest costs that weighed on FY26 profits. Although a large portion of the IPO proceeds will be used to repay debt, the company still needs its acquired hospitals to perform as expected. Some recently acquired businesses, including Sahyadri Hospitals, are still reporting losses. If their turnaround takes longer than anticipated, profitability could remain under pressure.

There are also execution risks associated with acquisitions. The balance sheet carries substantial goodwill, which represents the premium paid while acquiring businesses. If acquired hospitals fail to generate the expected returns, the company may have to write down part of this goodwill, reducing future profits. In addition, a large share of revenue comes from six major specialties, making earnings vulnerable if competition intensifies or demand shifts within these segments. Ongoing legal disputes involving certain leased hospital properties also remain an area worth watching.

Valuation & Peer Comparison

On the surface, the IPO appears expensive. At the upper price band, the company is seeking a post-IPO market capitalization of around ₹77,606 crore, translating into a P/E ratio of 84.67x, higher than Apollo Hospitals (66.15x), Fortis Healthcare (70.22x), and Max Healthcare (74.55x). Based only on this metric, investors may conclude that the IPO is aggressively priced.

However, hospitals are unusual businesses because they require heavy investments in land, buildings, equipment, and acquisitions. These create high depreciation and interest expenses, which reduce accounting profits even when the underlying business generates healthy operating cash flows. That is why EV/Adjusted EBITDA is often a more meaningful valuation metric for hospital companies.

On this basis, Manipal trades at 33.09x EV/Adjusted EBITDA, or 31.82x after considering a full-year contribution from Sahyadri Hospitals (recently acquired hospital). This places it below Apollo Hospitals (35.5x) and well below Fortis Healthcare (51.52x), while only modestly above Max Healthcare (28.2x). In other words, the valuation looks much more balanced once debt and operating earnings are considered together.

Operationally, the company also compares well with peers. It has one of the highest operating margins, the industry's shortest average patient stay, and the fastest recent revenue growth. Although its occupancy remains slightly lower than some competitors, faster patient turnover gives it room to increase volumes without immediately investing in new capacity. Considering its scale, strong cash generation, and expected reduction in debt after the IPO, the valuation appears more reasonable than the headline P/E ratio initially suggests.

Author's Take: Should You Consider This IPO?

Manipal Health brings together several qualities that long-term investors generally like to see: market leadership, strong revenue growth, efficient operations, healthy cash generation, and favorable industry tailwinds. The planned debt repayment should also improve its financial profile by reducing future interest costs.

At the same time, investors should not ignore the risks. The company still carries the legacy of debt-funded acquisitions, relies heavily on Karnataka for revenue, and needs recent acquisitions to deliver the expected returns. These factors could influence earnings over the next few years.

Overall, this looks like a cautiously positive IPO. The business quality appears strong, the healthcare industry offers long-term growth opportunities, and the valuation looks more reasonable when judged using operating metrics rather than headline earnings alone. Investors should weigh these strengths against the integration and execution risks before making their investment decision. For more IPOs, visit here.

Read the RA disclaimer here.